NCT06714045|Completed
Loading search results
Sponsor study identifier
observational
153
1 country
1
Study Start
September 12, 2001
Actual (reported)Primary Completion
June 22, 2024
Actual (reported)Study Completion
June 22, 2024
Actual (reported)We would like to emphasise the need to perform a biopsy in patients with suspected persistence/recurrence of disease; the need to carefully plan the access route to minimise the risk of false negatives; the possibility of performing biopsies through all minimally invasive access routes available to the thoracic surgeon ensuring rapid clinical recovery and timely resumption of medical treatment in the event of recurrence.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 22, 2024
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 12, 2001
Actual (reported)June 22, 2024
Actual (reported)June 22, 2024
Actual (reported)November 28, 2024
Actual (reported)December 3, 2024
Actual (reported)primary outcomes
Verify the need for histological confirmation in patients undergoing cytotoxic therapy for lymphoma presenting radiological/scintigraphic signs of suspected persistence or mediastinal recurrence of disease.
30 days after the surgery
secondary outcomes
30 days after the surgery
Patients who underwent needle biopsy or surgical biopsy for suspected persistence or recurrence of lymphoma after cytotoxic treatment at the IRCCS Azienda Ospedaliero-Universitaria di Bologna Thoracic Surgery between 1 January 2002 and 31 January 2023
IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, Emilia-Romagna, 40138, Italy
Sergio Nicola Forti Parri, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
153 participants (actual enrollment reported by the registry).
First Submitted
November 28, 2024
First Posted
December 3, 2024
Study Start
September 12, 2001
Actual (reported)Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
Contact the study team to confirm eligibility.
Primary Completion
June 22, 2024
Actual (reported)Study Completion
June 22, 2024
Actual (reported)Last Updated
December 3, 2024
Record last verified: 2024-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: